Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating pancreatic function in adults with type 2 diabetes to better understand both hormone production and digestive processes. This observational study aims to identify whether pancreatic problems can help detect pancreatogenic diabetes and how blood markers and pancreas structure relate to pancreatic function. The study is conducted as a cross-sectional, single-region, multisite investigation in outpatient clinics in the Aktobe region, Kazakhstan, focusing on adults with type 2 diabetes diagnosed within the past five years. Participants will attend a single visit during which blood tests will measure glucose, insulin, and other relevant markers. They will provide a stool sample to evaluate digestive function and undergo ultrasound imaging of the pancreas. Additionally, participants will answer questions about digestive symptoms to assess pancreatic exocrine function. The study groups include adults with type 2 diabetes who do not have exocrine pancreatic insufficiency based on fecal elastase-1 levels or questionnaire results. During the visit, researchers will collect and analyze various biochemical and imaging data, including fecal elastase-1, pancreatic ultrasound parameters, and blood markers such as C-peptide and glycated hemoglobin. Outcome measures will focus on the prevalence of pancreatogenic diabetes at the baseline visit. The study does not involve treatment but aims to improve diagnostic understanding through these comprehensive assessments. Total participation involves this single outpatient visit with no further follow-up required.
Actively Recruiting
Researchers are studying adults in Kazakhstan who have metabolic dysfunction-associated steatotic liver disease MASLD to better understand how this liver condition appears and is managed in everyday medical care. The study includes about 420 adults with MASLD, focusing on their health characteristics and how the disease affects them. A smaller group of about 65 participants in Almaty, who were already prescribed Ursosan by their doctors, will be followed to observe changes in liver-related health measures. The study has two parts a cross-sectional component where information from medical records, lab tests, liver imaging, and questionnaires is collected once for each participant and a prospective cohort component that follows the subgroup receiving Ursosan for approximately six months. During this follow-up, participants will have remote contacts at about 2 and 4 months and a final assessment at 6 months. Treatment decisions, including the use of Ursosan, are made by the participants doctors as part of routine care, not assigned by the study. Participants will provide data through routine medical care records, imaging scans, laboratory tests, and questionnaires about lifestyle and health. Researchers will measure liver health through imaging, liver enzyme levels, and fibrosis assessments. The study monitors changes in these measures over time, especially in the Ursosan subgroup. Participation may last up to six months for some, while others contribute data at a single time point, helping researchers understand MASLD and responses to Ursosan in real-world settings.
Actively Recruiting
Researchers are studying approximately 240 adult patients in Kazakhstan who have HER2-positive metastatic breast cancer mBC and are receiving anti-HER2 therapy, excluding trastuzumab deruxtecan. This observational retrospective study aims to evaluate real-world treatment approaches, clinical outcomes, and patient characteristics across 12 oncology centers to provide a representative sample of this population. The study covers patients diagnosed with mBC between January 2022 and December 2023 and includes a follow-up period to assess treatment impact. The study collects data retrospectively from patient medical records starting from the date of mBC diagnosis until either the patients death or the end of the study, which is at least 12 months after the latest diagnosis date. The treatments under review include all anti-HER2 therapies except trastuzumab deruxtecan. Researchers will analyze treatments received, diagnostic methods, therapy discontinuation reasons, lines of anticancer therapy, and efficacy in routine clinical practice. Participants data will be reviewed for at least 24 months following diagnosis, unless the patient died, moved, or refused therapy within that period. The primary outcome is to assess median progression-free survival and its rate over up to two years. Secondary outcomes include describing patient demographics, diagnostic and therapeutic patterns, treatment approaches, efficacy, reasons for stopping therapy, and number of therapy lines. This design involves no direct intervention, and data collection is based on existing medical records.
Actively Recruiting
This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.
Actively Recruiting
Researchers are evaluating the real-world effects of adding anifrolumab to standard treatment for patients with Systemic Lupus Erythematosus SLE. This multi-country observational study aims to gather important information on how anifrolumab works in routine clinical practice across various countries, including those in the Gulf Cooperation Council, Latin America, Taiwan, and Egypt. The study uses standardized criteria and assessments to compare results across these locations. Participants who have been prescribed anifrolumab for the first time will be followed prospectively for one year after their initial infusion. The study also collects data from the year before starting anifrolumab to understand baseline health status. Clinical assessments relevant to SLE, including specific measures for skin symptoms, are used to monitor the patients. The study continues to collect data even if patients stop anifrolumab treatment, unless they withdraw consent. During the study, participants will undergo clinical and patient-reported evaluations at baseline and multiple points over one year, including assessments like PGA, SLEDAI-2K, CLASI, FACIT-Fatigue, LupusQoL, and EQ-5D-5L. Researchers will monitor these outcomes to understand how patients respond to anifrolumab in everyday care. The study period continues until the end of 2027 or until patients discontinue participation, with careful follow-up to capture ongoing health information.